2. Academic Validation
  3. Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute

Technology evaluation: CC49 humanized radioimmunoconjugates, National Cancer Institute

  • Curr Opin Mol Ther. 2003 Aug;5(4):428-32.
Nadeem Sheikh 1
Affiliations

Affiliation

  • 1 Washington National Primate Research Center, Department of Pharmaceutics, University of Washington, 3000 Western Avenue, Seattle, WA 98121, USA. nadeem@bart.rprc.washington.edu
PMID: 14513687
Abstract

The National Cancer Institute and the University of Alabama are developing radiolabeled humanized versions of the anticarcinoma monoclonal antibody CC49 devoid of the CH2 domain (designated HuCC49 delta CH2). The antibody is currently undergoing phase I trials for the potential treatment of various tumors.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z